Treat patients with hyperlipidemia and presumed nonalcoholic fatty liver disease with atorvastatin to reduce the risk of cardiovascular events. Stength of recommendation: B: Based on a single prospective randomized controlled trial (RCT)
Patients with steatohepatitis who take HMG Co-A reductase inhibitors (statins) lower their elevated ...
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in West...
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the W...
BACKGROUND AND AIM: Non-alcoholic fatty liver disease (NAFLD) is a common disease associated with h...
AbstractNon-alcoholic fatty liver disease is an emerging liver disease in Western countries and the ...
BACKGROUND & AIMS: The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing, with c...
Non-alcoholic fatty liver disease is an emerging liver disease in Western countries and the most fre...
BACKGROUND/AIMS: Nonalcoholic steatohepatitis (NASH) is a serious disorder with the potential to gra...
Background: Nonalcoholic fatty liver disease (NAFLD) is a common complication in patients with metab...
INTRODUCTION: Nonalcoholic fatty liver disease (NAFLD) is associated with both dyslipidemia and incr...
Introduction: The use of statins in nonalcoholic fatty liver disease (NAFLD) may reduce cardiovascul...
Introduction The National Cholesterol Education Program periodicallyproduces Adult Treatment Panel (...
Introduction. Today, dyslipidaemia is considered one of the main risk factors for atherosclerosis an...
Nonalcoholic fatty liver disease (NAFLD) describes a spectrum of alcohol-like hepatic histological c...
Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are common causes...
Patients with steatohepatitis who take HMG Co-A reductase inhibitors (statins) lower their elevated ...
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in West...
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the W...
BACKGROUND AND AIM: Non-alcoholic fatty liver disease (NAFLD) is a common disease associated with h...
AbstractNon-alcoholic fatty liver disease is an emerging liver disease in Western countries and the ...
BACKGROUND & AIMS: The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing, with c...
Non-alcoholic fatty liver disease is an emerging liver disease in Western countries and the most fre...
BACKGROUND/AIMS: Nonalcoholic steatohepatitis (NASH) is a serious disorder with the potential to gra...
Background: Nonalcoholic fatty liver disease (NAFLD) is a common complication in patients with metab...
INTRODUCTION: Nonalcoholic fatty liver disease (NAFLD) is associated with both dyslipidemia and incr...
Introduction: The use of statins in nonalcoholic fatty liver disease (NAFLD) may reduce cardiovascul...
Introduction The National Cholesterol Education Program periodicallyproduces Adult Treatment Panel (...
Introduction. Today, dyslipidaemia is considered one of the main risk factors for atherosclerosis an...
Nonalcoholic fatty liver disease (NAFLD) describes a spectrum of alcohol-like hepatic histological c...
Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are common causes...
Patients with steatohepatitis who take HMG Co-A reductase inhibitors (statins) lower their elevated ...
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in West...
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the W...
Add to ORKG